Biomarkers for Diabetic Retinopathy Progression

  • Research type

    Research Study

  • Full title

    Retrospective Cohort Study of Imaging and Clinical Biomarkers for Predicting Disease Progression in Retinal Vascular Diseases

  • IRAS ID

    372934

  • Contact name

    Tariq Aslam

  • Contact email

    tariq.aslam@manchester.ac.uk

  • Sponsor organisation

    University of Manchester

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    Retinal vascular diseases, including diabetic retinopathy and retinal vein
    occlusions, are major causes of preventable sight loss in working-age adults.
    Some patients progress to more severe disease, which carries higher risk of vision
    loss. Currently, we cannot reliably predict which patients will progress.

    This research uses advanced retinal imaging (ultra-widefield OCT angiography) and
    clinical biomarkers to identify factors that predict disease progression in patients
    with retinal vascular diseases. We will examine routine clinical imaging scans and
    associated clinical data (such as blood sugar control, blood pressure, visual acuity,
    and treatment history) that have already been collected as part of standard eye care
    at Manchester Royal Eye Hospital.

    The study lasts for one year and is retrospective - we analyze existing data - but patients will be actively
    approached and asked for consent to use their data for research. Participation is
    voluntary and patients may decline or withdraw without affecting their clinical care.

    There is no new imaging or clinical procedures. All data used has been obtained during
    routine clinical care. We will work with pseudonymized (coded) data to protect patient
    privacy. Identifiable information will be accessed only by authorized NHS staff for
    data extraction and linking.

    By identifying which imaging features and clinical markers predict progression in
    retinal vascular diseases, we can help ophthalmologists identify high-risk patients
    earlier and provide more personalized care.

    The study will improve our understanding of how retinal vascular diseases progress
    and may lead to better surveillance strategies and treatment decisions for patients
    with these serious eye conditions.

  • REC name

    East Midlands - Nottingham 1 Research Ethics Committee

  • REC reference

    26/EM/0172

  • Date of REC Opinion

    4 Aug 2026

  • REC opinion

    Favourable Opinion